A Randomised Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Oct 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fulvestrant (Primary) ; Palbociclib (Primary) ; Anastrozole; Exemestane; Letrozole; Tamoxifen
Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer; Male breast cancer
Focus Therapeutic Use
Acronyms TRAK-ER

Most Recent Events

03 Oct 2024 New source identified and integrated (European Clinical Trials Database;EudraCT2020-004022-36).
10 Dec 2022 Trial design presented at the 45th Annual San Antonio Breast Cancer Symposium.
19 May 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight